2 recruiting, 1 active not recruiting, 1 completed. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Facioscapulohumeral Muscular Dystrophy 1B: new trials by email Literature Review of Facioscapulohumeral Muscular Dystrophy 1B trials Research Report on Facioscapulohumeral Muscular Dystrophy 1B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD AOC-1020, Placebo - Facioscapulohumeral Muscular Dystrophy, FSHD | Phase 3 | Recruiting | Avidity Biosciences, Inc. | 200 | 2025-06-10 | 2026-07-27 |
| BetterLife FSHD: A Patient-driven Health and Research Platform Observational - FSH, FSH Muscular Dystrophy | Recruiting | FSHD Society | 5000 | 2024-08-02 | 2026-02-20 | |
| Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 - FSHD, FSHD1 | Phase 2 | Active not recruiting | Avidity Biosciences, Inc. | 84 | 2024-07-25 | 2026-07-14 |
| Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020, Placebo - FSHD, FSHD1 | Phase 1 / Phase 2 | Completed | Avidity Biosciences, Inc. | 90 | 2023-04-04 | 2026-07-16 |
Muscular Dystrophy, Facioscapulohumeral (4) · Facioscapulohumeral muscular dystrophy 1a (3) · Muscular Dystrophies (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Muscular Diseases (4) · Muscular Disorders, Atrophic (4) · Musculoskeletal Diseases (4) · Nervous System Diseases (4) · Neuromuscular Diseases (4) · Muscular Dystrophies (2)
Sodium Chloride (2) · Watchful Waiting (1)
Avidity Biosciences, Inc. (3) · FSHD Society (1)
United States (4) · Canada (3) · United Kingdom (3) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Spain (1)
Amanda Hill, MBA (1)